231 related articles for article (PubMed ID: 36130755)
1. ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial.
Dirikgil E; van Leeuwen JR; Bredewold OW; Ray A; Jonker JT; Soonawala D; Remmelts HHF; van Dam B; Bos WJ; van Kooten C; Rotmans J; Rabelink T; Teng YKO
BMJ Open; 2022 Sep; 12(9):e061339. PubMed ID: 36130755
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly.
Aqeel F; Xu L; Salas A; Wen Y; Eid SM; Geetha D
Clin Rheumatol; 2023 Sep; 42(9):2427-2435. PubMed ID: 37225927
[TBL] [Abstract][Full Text] [Related]
3. Rituximab Versus Cyclophosphamide for Central Nervous System Involvement of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Case Series.
Krishna R; De Giacomi F; Kumar N; Kalina P; Specks U; Baqir M
J Clin Rheumatol; 2021 Mar; 27(2):64-72. PubMed ID: 31567753
[TBL] [Abstract][Full Text] [Related]
4. Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial.
Furuta S; Sugiyama T; Umibe T; Kaneko Y; Amano K; Kurasawa K; Nakagomi D; Hiraguri M; Hanaoka H; Sato Y; Ikeda K; Nakajima H;
BMJ Open; 2017 Dec; 7(12):e018748. PubMed ID: 29247107
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Viviano L; Ding L; Iklé D; Villarreal M; Jepson B; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Stone JH;
Arthritis Rheumatol; 2014 Nov; 66(11):3151-9. PubMed ID: 25047592
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
[TBL] [Abstract][Full Text] [Related]
7. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
[TBL] [Abstract][Full Text] [Related]
8. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
[TBL] [Abstract][Full Text] [Related]
9. Novel Therapies for ANCA-associated Vasculitis.
Monti S; Brandolino F; Milanesi A; Xoxi B; Delvino P; Montecucco C
Curr Rheumatol Rep; 2021 Apr; 23(6):38. PubMed ID: 33909172
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
11. B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.
Kallenberg CG; Hauser T
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i119-22. PubMed ID: 25753806
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
14. Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: A retrospective study.
Ysermans R; Busch MH; Aendekerk JP; Damoiseaux JGMC; van Paassen P
J Transl Autoimmun; 2023; 6():100178. PubMed ID: 36589266
[TBL] [Abstract][Full Text] [Related]
15. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
[TBL] [Abstract][Full Text] [Related]
16. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?
Kallenberg CG
Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946
[TBL] [Abstract][Full Text] [Related]
17. How best to manage relapse and remission in ANCA-associated vasculitis.
Puéchal X; Guillevin L
Expert Rev Clin Immunol; 2022 Nov; 18(11):1135-1143. PubMed ID: 36102147
[TBL] [Abstract][Full Text] [Related]
18. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.
Smith RM; Jones RB; Specks U; Bond S; Nodale M; Al-Jayyousi R; Andrews J; Bruchfeld A; Camilleri B; Carette S; Cheung CK; Derebail V; Doulton T; Ferraro A; Forbess L; Fujimoto S; Furuta S; Gewurz-Singer O; Harper L; Ito-Ihara T; Khalidi N; Klocke R; Koening C; Komagata Y; Langford C; Lanyon P; Luqmani R; McAlear C; Moreland LW; Mynard K; Nachman P; Pagnoux C; Peh CA; Pusey C; Ranganathan D; Rhee RL; Spiera R; Sreih AG; Tesar V; Walters G; Wroe C; Jayne D; Merkel PA;
Ann Rheum Dis; 2023 Jul; 82(7):937-944. PubMed ID: 36958796
[TBL] [Abstract][Full Text] [Related]
19. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
20. [State of art and new perspectives in the induction regimen of ANCA-associated vasculitis with renal involvement: from histopathology to therapy].
Uzzo M; Alberici F
G Ital Nefrol; 2021 Feb; 38(1):. PubMed ID: 33599423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
